Anika Therapeutics (ANIK) Invested Capital (2010 - 2022)

Anika Therapeutics (ANIK) has reported Invested Capital for 8 consecutive years, with $285.6 million the latest figure, recorded in Q4 2022.

• On a quarterly basis, Invested Capital fell 2.0% year-over-year to $285.6 million in Q4 2022; TTM through Dec 2022 was $285.6 million, a 2.0% decrease from a year earlier, with the FY2022 full-year figure at $285.6 million, down 2.0% from the prior year.
• Invested Capital was $285.6 million for Q4 2022 at Anika Therapeutics, roughly flat from $284.9 million in the prior quarter.
• Over five years, Invested Capital peaked at $338.4 million in Q2 2020 and troughed at $284.9 million in Q3 2022.
• A 4-year average of $296.9 million and a median of $290.9 million in 2021 frame the typical range for Invested Capital.
• The widest YoY moves for Invested Capital: up 2.07% in 2021, down 10.27% in 2021.
• Over 4 years, Invested Capital stood at $288.4 million in 2019, then slipped by 1.0% to $285.5 million in 2020, then climbed by 2.07% to $291.4 million in 2021, then fell by 2.0% to $285.6 million in 2022.
• The last three Invested Capital figures came in at $285.6 million (Q4 2022), $284.9 million (Q3 2022), and $290.5 million (Q2 2022), per Business Quant data.